Zoetis announced today it has received an expanded label approval from the Food and Drug Administration’s Center for Veterinary Medicine (CVM) for Synovex® ONE Grower increased rate of weight gain for up to 200 days in growing beef steers and heifers in a dry lot.
“This approval gives dry lot cattle producers a long-acting implant option to support longer term dry lot periods, whether in confinement or on pasture with insufficient forage quality/yield. As one of only three implants containing trenbolone acetate (TBA) approved for dry lot production, it supports additional weight gain for up to 200 days in growing beef steers and heifers when paired with proper nutrition,” said Jase Ball, PhD, associate director of Global Clinical Research and Development at Zoetis.
Effective immediately, existing packages of Synovex® ONE Grower can be used in the dry lot production phase. Animal health product suppliers and cattle producers will begin seeing packaging for Synovex® ONE Grower with the updated indications by the end of 2026.
“The approval of Synovex® ONE Grower in the dry lot production phase adds one more tool in the toolbox for dry lot and integrated operations, especially those that are needing extra days of implant coverage in their production systems” said Dirk Burken, PhD, MBA nutritionist with Zoetis Beef Strategic Technical Services. “It’s exciting to be able to offer this added flexibility and value to our growing cattle customers. This approval further reflects Zoetis’s commitment to implant technology and, most importantly, to our customers.”
For more information on how the expanded label could fit your operation, please visit with your Zoetis sales representative. You also can visit www.Synovex.com to learn more.
Refer to individual labels for complete directions for use, precautions, and warnings.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
